Clinical trial
Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy
NCT05167721 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy
- Lead sponsor
- Mayo Clinic
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- December 15, 2021
- Completion date
- December 31, 2026
- Enrollment
- 71 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.